Pipeline

Overview

MacroGenics has a diverse portfolio of oncology product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly (as of December 2022).

In addition to the molecules identified below, MacroGenics has out-licensed various other clinical-stage product candidates for which it retains certain economic rights. These include retifanlimab and teplizumab.

Program (Target)	Potential Indication(s)	First-in-Human (Phase 1)	Proof-of-Concept (Phase 2)	Pivotal (Phase 3)	Major Market Rights
Vobramitamab Duocarmazine (MGC018) (B7-H3)	mCRPC (TAMARACK study)	placeholder
	Multiple Solid Tumors (+lorigerlimab)	placeholder
Lorigerlimab (PD-1 × CTLA-4)	mCRPC, Melanoma, MSS CRC, NSCLC	placeholder
Tebotelimab (PD-1 × LAG-3)	Solid Tumors & Heme Malignancies	placeholder					Greater China
MGD024 (CD123 × CD3)	CD123+ Heme Malignancies	placeholder					Option Agreement
IMGC936 (ADAM9)	Multiple Solid Tumors	placeholder				50/50

Oncology

Vobramitamab Duocarmazine (MGC018) (B7-H3)

mCRPC (TAMARACK study)

Phase 1	Phase 2	Phase3
placeholder

Multiple Solid Tumors (+lorigerlimab)

Phase 1	Phase 2	Phase3
placeholder

Major Market Rights:

Lorigerlimab
(PD-1 × CTLA-4)

mCRPC, Melanoma, MSS CRC, NSCLC

Phase 1	Phase 2	Phase3
placeholder

Major Market Rights:

Tebotelimab
(PD-1 × LAG-3)

Solid Tumors & Heme Malignancies

Phase 1	Phase 2	Phase3
placeholder

Major Market Rights:

Greater China

MGD024
(CD123 × CD3)

CD123+ Heme Malignancies

Phase 1	Phase 2	Phase3
placeholder

Major Market Rights:

Option Agreement

IMGC936
(ADAM9)

Multiple Solid Tumors

Phase 1	Phase 2	Phase3
placeholder

Major Market Rights:

50/50